Self-Assessment Post-Test
SELF-ASSESSMENT POST-TEST There are no fees for participating and receiving CME credit for this activity. During the period March 2005 through March 31, 2006, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key to the Postgraduate Institute for Medicine. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better. Your statement of credit will be mailed to you within 4 weeks. Selective Estrogen Receptor Modulators in Prevention of Prostate Cancer and Osteoporosis: Rationale and Clinical Implications 1. 2. 3. 4. 5. 6. 7. Which of the following is (are) true of diethylstilbestrol? a. suppresses pituitary secretion of luteinizing hormone b. decreases testicular testosterone production c. leads to androgen-refractory prostate cancer d. has a relatively high incidence of cardiovascular complications e. all of the above According to Dr. Bosland, it is likely that increased circulating estrogens, particularly in the presence of decreased testosterone, may increase the risk of prostate cancer. a. true b. false Chemoprevention of prostate cancer will probably require which of the following characteristics? a. antiestrogenic b. antiandrogenic c. antioxidant d. all of the above The presence of prostatic intraepithelial neoplasia (PIN): a. decreases with age b. increases with androgen deprivation therapy c. indicates a higher risk for development of prostate cancer d. is higher in Caucasian men than in African American men Indicators of being at a high risk for development of prostate cancer is (are): a. family history of prostate cancer in a first-degree relative b. race c. presence of high-grade intraepithelial neoplasia (HGPIN) d. all of the above According to Dr. Taneja, how strong is the implication of HGPIN as a cancer precursor? a. weak likelihood b. moderate likelihood c. high likelihood Dr. Taneja and associates recommend a minimum ____-core sampling of the prostate peripheral zone for patients with HGPIN. a. 6 b. 8 c. 10 d. 12 8. Following a finding of HGPIN, Dr. Taneja and associates recommend repeat biopsy in ____ years. a. 1 to 1 12 b. 2 to 3 c. 3 to 5 9. PSA alone is a valid indicator of progression from HGPIN to cancer of the prostate. a. true b. false 10. Stimulation of estrogen receptor- (ER-) tends to ___________ prostate progression whereas stimulation of estrogen receptor- (ER-) acts to __________ prostate progression. a. stimulate; suppress b. suppress; stimulate 11. In a Phase II trial conducted in men with HGPIN, a statistically significant rate of cancer reduction was found at which dose? a. 20 mg b. 40 mg c. 60 mg d. 80 mg 12. The ___________ is the preferred skeletal site to screen men for osteoporosis using DEXA. a. wrist b. lumbar spine c. hip 13. Retrospective studies have consistently reported high rates of clinical fracture in GnRH agonist-treated men with prostate cancer. a. true b. false 14. Research in postmenopausal women revealed a reduced rate of bone loss when treated with raloxifene, a selective estrogen receptor modulator. When men with nonmetastatic cancer of the prostate were given raloxifene in an open-label study, the results revealed that the men treated with raloxifene: a. had no improvement in bone mineral density (BMD) b. showed a small but not statistically significant improvement in BMD c. had an increased BMD of the hip d. showed no improvement in BMD of the spine EVALUATION FORM Selective Estrogen Receptor Modulators in Prevention of Prostate Cancer and Osteoporosis: Rationale and Clinical Implications Project ID: 2421 ES 13 Postgraduate Institute for Medicine (PIM) respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. You must complete this evaluation form to receive acknowledgement of participation for this activity. Please Print Clearly Name: Address: City/State: Phone Number: E-mail: Specialty: Box/Suite: Zip Code: Fax Number: VOL. 7 SUPPL. 3 2005 REVIEWS IN UROLOGY S37 Please answer the following questions by circling the appropriate rating: 5 = Outstanding 4 = Good 3 = Satisfactory 2 = Fair 1 = Poor EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES Upon completion of this activity, participants should be better able to: • Discuss the role of estrogens in prostate growth and carcinogenesis 5 4 • Review the data regarding prostatic intraepithelial neoplasia and prevention of prostate cancer 5 4 • Describe the data regarding the use of drug therapy for prevention of adverse events associated with gonadotropin-releasing hormone agents 5 4 OVERALL EFFECTIVENESS OF THE ACTIVITY • Was timely and will influence how I practice • Will assist me in improving patient care • Fulfilled my educational needs • Avoided commercial bias or influence 5 5 5 5 4 4 4 4 3 2 1 3 2 1 3 2 1 3 3 3 3 2 2 2 2 1 1 1 1 IMPACT OF THE ACTIVITY The information presented: (check all that apply) ❒ Reinforced my current practice/treatment habits ❒ Provided new ideas or information I expect to use ❒ Will improve my practice/patient outcomes ❒ Enhanced my current knowledge base Will the information presented cause you to make any changes in your practice? If yes, please describe any change(s) you plan to make in your practice as a result of this activity: How committed are you to making these changes? (Very committed) 5 4 3 2 Yes___ No___ 1 (Not at all committed) FUTURE ACTIVITIES Do you feel future activities on this subject matter are necessary and/or important to your practice? ❒ Yes ❒ No Please list any other topics that would be of interest to you for future educational activities: FOLLOW-UP As part of our ongoing continuous quality-improvement effort, we conduct post-activity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey: ❒ Yes, I would be interested in participating in a follow-up survey ❒ No, I’m not interested in participating in a follow-up survey Additional comments about this activity: POST-TEST ANSWER KEY ❒ I participated in the entire activity and claim 2.5 credits. ❒ I participated in only part of the activity and claim _____ credits. If you wish to receive acknowledgement of participation for this activity, please complete the post-test by selecting the best answer to each question, complete this evaluation verification of participation, and FAX to: 303-790-4876 or MAIL to: Postgraduate Institute for Medicine, P.O. Box 260620, Littleton, CO, 80163. Signature Date Completed 1___ 2___ 3___ 4___ 5___ 6___ 7___ 8___ 9___ 10___ 11___ 12___ 13___ 14___ I certify my actual time spent to complete this educational activity to be: S38 VOL. 7 SUPPL. 3 2005 REVIEWS IN UROLOGY